Open AccessThe role of PD-1/PD-L1 inhibitors in the treatment for non-small cell lung cancer (NSCLC)
Author(s) -
Li Che,
Manyi Xu
Publication year - 2022
Publication title -
highlights in science, engineering and technology
Language(s) - English
Resource type - Journals
ISSN - 2791-0210
DOI - 10.54097/hset.v8i.1108
Subject(s) - durvalumab , atezolizumab , pembrolizumab , nivolumab , avelumab , pd l1 , non small cell lung cancer (nsclc) , medicine , lung cancer , oncology , immunotherapy , chemotherapy , cancer research , cancer , a549 cell